Heightman, Tom D.’s team published research in Journal of Medicinal Chemistry in 2021 | CAS: 3934-20-1

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chlorides are compounds containing a carbon-chlorine bond, which are widely used in the oil field as a wax dissolver. They are generally not present in crude oils and are typically the result of additives, cleaning solutions or chemicals used for oil recovery.Recommanded Product: 3934-20-1

Recommanded Product: 3934-20-1In 2021 ,《Discovery of ASTX029, A Clinical Candidate Which Modulates the Phosphorylation and Catalytic Activity of ERK1/2》 was published in Journal of Medicinal Chemistry. The article was written by Heightman, Tom D.; Berdini, Valerio; Bevan, Luke; Buck, Ildiko M.; Carr, Maria G.; Courtin, Aurelie; Coyle, Joseph E.; Day, James E. H.; East, Charlotte; Fazal, Lynsey; Griffiths-Jones, Charlotte M.; Howard, Steven; Kucia-Tran, Justyna; Martins, Vanessa; Muench, Sandra; Munck, Joanne M.; Norton, David; O’Reilly, Marc; Palmer, Nicholas; Pathuri, Puja; Peakman, Torren M.; Reader, Michael; Rees, David C.; Rich, Sharna J.; Shah, Alpesh; Wallis, Nicola G.; Walton, Hugh; Wilsher, Nicola E.; Woolford, Alison J.-A.; Cooke, Michael; Cousin, David; Onions, Stuart; Shannon, Jonathan; Watts, John; Murray, Christopher W.. The article contains the following contents:

Aberrant activation of the mitogen-activated protein kinase pathway frequently drives tumor growth, and the ERK1/2 kinases are positioned at a key node in this pathway, making them important targets for therapeutic intervention. Recently, a number of ERK1/2 inhibitors have been advanced to investigational clin. trials in patients with activating mutations in B-Raf proto-oncogene or Ras. Here, we describe the discovery of the clin. candidate ASTX029 (15)(I) through structure-guided optimization of our previously published isoindolinone lead (7). The medicinal chem. campaign focused on addressing CYP3A4-mediated metabolism and maintaining favorable physicochem. properties. These efforts led to the identification of ASTX029, which showed the desired pharmacol. profile combining ERK1/2 inhibition with suppression of phospho-ERK1/2 (pERK) levels, and in addition, it possesses suitable preclin. pharmacokinetic properties predictive of once daily dosing in humans. ASTX029 is currently in a phase I-II clin. trial in patients with advanced solid tumors. In the experimental materials used by the author, we found 2,4-Dichloropyrimidine(cas: 3934-20-1Recommanded Product: 3934-20-1)

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chlorides are compounds containing a carbon-chlorine bond, which are widely used in the oil field as a wax dissolver. They are generally not present in crude oils and are typically the result of additives, cleaning solutions or chemicals used for oil recovery.Recommanded Product: 3934-20-1

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia